ThermoGenesis launches new cell processing products

By The Science Advisory Board staff writers

June 23, 2020 -- ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global distribution agreement.

The X-Series systems provide fast, sterile, automated, and efficient processing of human blood and blood products to obtain purified populations of immune cells for use in gene and cell therapy applications. The density gradient media-free and buoyancy-activated cell sorting (X-BACS) technology, which uses a novel microbubble approach without magnetic beads, was designed to support the increased demand for chimeric antigen receptor (CAR)-T cell therapies for personalized immunotherapies to treat blood cancers.

The platform includes several products such as X-Lab for automation and harvest of mononuclear immune cells and X-Wash for high-throughput cell processing. Additionally, the X-Mini selection kit uses the X-BACS technology for cell sorting.

ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics...

Copyright © 2020 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter